Xcellerex Announces Appointment of Guy Broadbent as President and Chief Executive Officer

Xcellerex Announces Appointment of Guy Broadbent as President and Chief Executive Officer
Broadbent to lead Company through next phase of growth

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Xcellerex, Inc. announced today that Guy Broadbent has been appointed President and Chief Executive Officer and a member of the company's board of directors. Mr. Broadbent succeeds Joseph Zakrzewski, who served as Chairman, President and CEO, as part of an existing management succession process planned as the company begins its next phase in commercializing its novel single-use biomanufacturing technology, proprietary services and biomolecules businesses. Mr. Zakrzewski will remain on the Board of Directors as Chairman.

Mr. Broadbent joins Xcellerex after a 25-year career, including substantial experience in the life sciences sector, most recently at Thermo Fisher Scientific where he served in a number of senior positions, including President of the $1.8 billion Laboratory Products Division, and most recently, Senior Vice President, Corporate Development.

Mr. Zakrzewski, who joined Xcellerex as President and CEO in May 2007, stated, "Guy's skills and experience, including his deep commercial background within the industry, are a great fit with our businesses and will help drive Xcellerex's future growth. Our biomanufacturing technology has now been validated through its use in over 20 products in development, including Xcellerex's proprietary Yellow Fever vaccine candidate currently in a Phase 1 clinical trial. We successfully commercialized our novel disposable bioreactors and FlexFactory® product lines, and grew our complementary services business. I am thankful for the opportunity to have led Xcellerex over the last three years."

"I am excited to be joining Xcellerex at this critical point in its growth," commented Mr. Broadbent. "I look forward to working closely with the Board, management, and employees of Xcellerex to continue the tradition of innovation and manufacturing excellence that will enable us to grow sales rapidly as we serve our customers globally.

"Guy brings an outstanding track record of commercial success in the life science industry and in-depth knowledge of biomanufacturing products," said Thomas Monath, MD, a partner at Kleiner Perkins Caufield & Byers, member of Xcellerex's board of directors, and Chair of the search committee. The Board would like to thank Joe Zakrzewski for his significant contributions to Xcellerex, which has made great progress under his leadership. We are pleased he will remain active with the company as Chairman."

About FlexFactory

Xcellerex's FlexFactory is an innovative, portable manufacturing platform, based on the innovative application of (1) single-use technologies; (2) controlled environmental modules (CEMs); and (3) advanced and proven process automation including electronic batch records. The FlexFactory effectively eliminates clean and steam-in-place and clean room infrastructure, greatly simplifies facility design, reducing manufacturing footprint and capital investment, and creates breakthrough gains in operating efficiency, flexibility and environmental friendliness.

About Xcellerex, Inc.

Xcellerex is revolutionizing the way biomolecules are developed, manufactured and commercialized. The company's unique single-use component technology platform transforms biomanufacturing economics, enabling the development of biotherapeutics and vaccines, and dramatically improving the ability of Xcellerex and its partners to deploy manufacturing capacity. Xcellerex leverages its technology and services platform by: 1) commercializing its FlexFactories® (complete, turnkey, modular production trains) and XDR (unique, single use component bioreactor systems); 2) building a portfolio of proprietary biotherapeutics and vaccines through creative alliances and in licensing; and 3) creatively structuring transactions around FlexFactories, XDRs and its pipeline. Based in Marlborough, Massachusetts, Xcellerex is backed by an experienced management team and top-tier venture investors including Kleiner Perkins Caufield & Byers, VantagePoint Venture Partners and SCG Capital. For more information, please visit the company's website at http://www.xcellerex.com


Contacts
Xcellerex, Inc.
Jonathan Lieber, 508-683-2239
Chief Financial Officer
or
RMG Associates
Robert Gottlieb, 857-891-9091

 

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.